Company intelligence / Profile preview
Ariceum Therapeutics
Berlin, Berlin, Germanyariceum-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has received FDA clearance for its IND application to commence a Phase I/II clinical trial ('SANTANA-225') of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). The company also has a radiolabelled PARP-inhibitor (ATT001) currently in Phase 1 clinical development under the trial name CITADEL-123[4][9].
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceuticalstargeted systemic radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
ITM Isotope Technologies Munich SENorthStar Medical RadioisotopesEckert & ZieglerUCB Pharma
Beyond the preview
Go deeper on Ariceum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ariceum Therapeutics.